Classical dopamine agonists

  title={Classical dopamine agonists},
  author={Reinhard Horowski and Peter Andreas L{\"o}schmann},
  journal={Journal of Neural Transmission},
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson’s disease (PD) with l-DOPA and subsequently dopaminergic drugs. Parenteral apomorphine has a short lasting effect in PD, bromocriptine can be administered orally… 
6 Citations

Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes

  • K. Aoyama
  • Medicine, Psychology
  • 2019
In this chapter, therapy with parkinsonian drugs and their pharmacological properties, including adverse effects and influence on disease progression, will be discussed in detail.

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia‐associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus and various other diseases in a variety of dosage forms for best possible beneficial effects.

Ameliorative role of Syzygium aromaticum aqueous extract on synaptosomal tyrosine hydroxylase activity, oxidative stress parameters, and behavioral changes in lead-induced neurotoxicity in mice.

The findings showed that S. aromaticum possesses antioxidant and neuro-modulatory potential against lead-induced neuronal damage and could be suggested as a neuroprotective molecule against neurodegenerative diseases involving catecholaminergic dysfunction induced by metallic elements.

Behavioural abnormalities and novel pharmaceutical intervention in acute and developmental rat models of psychiatric illness

This chapter discusses the role of dopamine, glutamate, and cytokine in the development of psychiatric illness and their role in the design of models for this illness.



Use of apomorphine in Parkinson’s disease

  • F. Stocchi
  • Biology, Medicine
    Neurological Sciences
  • 2008
In the parkinsonian patient, the striatal levels of dopamine strictly depend on peripheral levodopa levels; short half-life of levodopa is responsible for plasmatic level fluctuations, which are

The motor effects of bromocriptine — a review

The present review explores the literature on the motor effects of bromocriptine and endeavours to integrate its behavioural, biochemical and electrophysiological effects into a coherent whole and suggests some future studies.

Bromocriptine in Parkinsonism

Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were

Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis

The present findings do not support the hypothesis that the hallucinogenic effect of LSD is reflected by variations in the level and turnover of the brain amines, and a stimulation of 5-HT autoreceptors is also evident after the non-hallucinogenic lisuride.

Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis

The data do not support the concept of a class effect suggesting that all ergot-derived drugs and especially DA receptor agonists with some chemical similarity to the ergot structure will cause or facilitate cardiac valvulopathies as observed with pergolide.

Evidence for dopamine receptor stimulation by apomorphine

Supporting evidence for apomorphine acts on the dopamine receptors whereas amphetamine acts by releasing dopamine is given by further functional, biochemical and histochemical studies.

Continuous dopaminergic stimulation: state of the art and outlook.

Therapy with L-Dopa was a major break-through in the treatment of Parkinson’s disease. It was an important precedent, and a stimulus for research in this and other fields of neurology. Initial side

Transdermal lisuride delivery in the treatment of Parkinson's disease.

This observational study demonstrates the safety, tolerability and efficacy of transdermal lisuride delivery in the treatment of motor complications.

Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.

The continuous dopaminergic stimulation provided by infusion of dopamine agonist drugs, is a very effective strategy to control ON-OFF fluctuation in Parkinson's disease and is shown to be effective when applied in combination with oral levodopa.